Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy

Wei-Ciao Wu, Yau-Lin Tseng, Yi-Ting Yen, Wu-Wei Lai

Research output: Contribution to journalArticle

Abstract

The role of surgical resection after tyrosine-kinase inhibitor (TKI) treatment in locally advanced NSCLC remains controversial. There have benn scanty case reports of successful treatment outcome resulting from complete resection post-TKI response. However, there is no consensus on indication or timing of surgical resection in locally advanced NSCLC treated with TKIs. We present the cases of 10 patients with NSCLC stage IIIa~VI who received TKIs as first-line treatment. Surgical resection was performed in various situations, including those in which complete resection could be achieved and those in which the patient could not withstand the adverse effects of TKI. Surgical outcomes and survival patterns were acceptable. TKIs can be used as neoadjuvant therapy, but further research should indicate the timing of surgery and the criteria of patient selection. We believe future clinical trial should be conducted to evaluate this treatment modality.
Original languageEnglish
Pages (from-to)236-242
Number of pages7
Journal胸腔醫學
Volume31
Issue number4
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Protein-Tyrosine Kinases
Patient Selection
Therapeutics
Clinical Trials
Survival
Research

Keywords

  • 酪氨酸激酶抑制劑
  • 前導治療
  • 非小細胞肺癌
  • tyrosine kinase inhibitor
  • neoadjuvant
  • non small cell lung cancer

Cite this

Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy. / Wu, Wei-Ciao ; Tseng, Yau-Lin; Yen, Yi-Ting; Lai, Wu-Wei.

In: 胸腔醫學, Vol. 31, No. 4, 2016, p. 236-242.

Research output: Contribution to journalArticle

Wu, Wei-Ciao ; Tseng, Yau-Lin ; Yen, Yi-Ting ; Lai, Wu-Wei. / Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy. In: 胸腔醫學. 2016 ; Vol. 31, No. 4. pp. 236-242.
@article{aaa922e8f76042dd86e67a5f8c78b7dc,
title = "Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy",
abstract = "The role of surgical resection after tyrosine-kinase inhibitor (TKI) treatment in locally advanced NSCLC remains controversial. There have benn scanty case reports of successful treatment outcome resulting from complete resection post-TKI response. However, there is no consensus on indication or timing of surgical resection in locally advanced NSCLC treated with TKIs. We present the cases of 10 patients with NSCLC stage IIIa~VI who received TKIs as first-line treatment. Surgical resection was performed in various situations, including those in which complete resection could be achieved and those in which the patient could not withstand the adverse effects of TKI. Surgical outcomes and survival patterns were acceptable. TKIs can be used as neoadjuvant therapy, but further research should indicate the timing of surgery and the criteria of patient selection. We believe future clinical trial should be conducted to evaluate this treatment modality.",
keywords = "酪氨酸激酶抑制劑, 前導治療, 非小細胞肺癌, tyrosine kinase inhibitor, neoadjuvant, non small cell lung cancer",
author = "Wei-Ciao Wu and Yau-Lin Tseng and Yi-Ting Yen and Wu-Wei Lai",
year = "2016",
language = "English",
volume = "31",
pages = "236--242",
journal = "胸腔醫學",
issn = "1023-9855",
publisher = "臺灣胸腔暨重症加護醫學會",
number = "4",

}

TY - JOUR

T1 - Feasibility of Surgery for Advanced NSCLC Treated with Tyrosine Kinase Inhibitors as Neoadjuvant Therapy

AU - Wu, Wei-Ciao

AU - Tseng, Yau-Lin

AU - Yen, Yi-Ting

AU - Lai, Wu-Wei

PY - 2016

Y1 - 2016

N2 - The role of surgical resection after tyrosine-kinase inhibitor (TKI) treatment in locally advanced NSCLC remains controversial. There have benn scanty case reports of successful treatment outcome resulting from complete resection post-TKI response. However, there is no consensus on indication or timing of surgical resection in locally advanced NSCLC treated with TKIs. We present the cases of 10 patients with NSCLC stage IIIa~VI who received TKIs as first-line treatment. Surgical resection was performed in various situations, including those in which complete resection could be achieved and those in which the patient could not withstand the adverse effects of TKI. Surgical outcomes and survival patterns were acceptable. TKIs can be used as neoadjuvant therapy, but further research should indicate the timing of surgery and the criteria of patient selection. We believe future clinical trial should be conducted to evaluate this treatment modality.

AB - The role of surgical resection after tyrosine-kinase inhibitor (TKI) treatment in locally advanced NSCLC remains controversial. There have benn scanty case reports of successful treatment outcome resulting from complete resection post-TKI response. However, there is no consensus on indication or timing of surgical resection in locally advanced NSCLC treated with TKIs. We present the cases of 10 patients with NSCLC stage IIIa~VI who received TKIs as first-line treatment. Surgical resection was performed in various situations, including those in which complete resection could be achieved and those in which the patient could not withstand the adverse effects of TKI. Surgical outcomes and survival patterns were acceptable. TKIs can be used as neoadjuvant therapy, but further research should indicate the timing of surgery and the criteria of patient selection. We believe future clinical trial should be conducted to evaluate this treatment modality.

KW - 酪氨酸激酶抑制劑

KW - 前導治療

KW - 非小細胞肺癌

KW - tyrosine kinase inhibitor

KW - neoadjuvant

KW - non small cell lung cancer

M3 - Article

VL - 31

SP - 236

EP - 242

JO - 胸腔醫學

JF - 胸腔醫學

SN - 1023-9855

IS - 4

ER -